title: Gene signatures of breast cancer progression and metastasis.
abstract: Breast cancer is a heterogeneous disease. Patient outcome varies significantly, depending on prognostic features of patients and their tumors, including patient age, menopausal status, tumor size and histology, nodal status, and so on. Response to treatment also depends on a series of predictive factors, such as hormone receptor and HER2 status. Current treatment guidelines use these features to determine treatment. However, these guidelines are imperfect, and do not always predict response to treatment or survival. Evolving technologies are permitting increasingly large amounts of molecular data to be obtained from tumors, which may enable more personalized treatment decisions to be made. The challenge is to learn what information leads to improved prognostic accuracy and treatment outcome for individual patients.
authors.affiliation: London Regional Cancer Program, Cancer Research Laboratories, London Health Sciences Centre, 790 Commissioners Road East, London, Ontario, N6A 4L6, Canada.
authors.forename: David I
authors.initials: DI
authors.lastname: Rodenhiser
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Andrews
authors.forename: Theodore A
authors.initials: TA
authors.lastname: Vandenberg
authors.forename: Ann F
authors.initials: AF
authors.lastname: Chambers
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D009362:Neoplasm Metastasis; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor